SCHEDULE: Goldman Sachs Discloses 4.1% Stake in Oaktree III Life
Beneficial Ownership Report
Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC have reported a 4.1% beneficial ownership stake in Oaktree Acquisition Corp. III Life Sciences.
Summary
- The Goldman Sachs Group, Inc. and its subsidiary, Goldman Sachs & Co. LLC, jointly reported beneficial ownership of 803,487 Class A ordinary shares of Oaktree Acquisition Corp. III Life Sciences.
- This ownership represents 4.1% of the Class A ordinary shares outstanding.
- Both entities hold shared voting power and shared dispositive power over all 803,487 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership, with no positive or negative operational implications for the issuer or the reporting entities beyond the ownership stake itself.
Future Outlook
N/A
Management Comments
- The securities referred to were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing indicates a significant financial institution's passive investment in a Special Purpose Acquisition Company (SPAC) focused on life sciences, a common practice for large investment firms to hold stakes in various public entities.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC updated their Power of Attorney, effective July 16, 2025, superseding previous authorizations. This grants specific individuals the authority to execute SEC filings on their behalf. | 2025-07-16 | This is an internal administrative update for the reporting entities, ensuring proper authorization for regulatory filings. It has no direct impact on the corporate governance of Oaktree Acquisition Corp. III Life Sciences. |
Stakeholder Impact
- Shareholders of Oaktree Acquisition Corp. III Life Sciences: Provides transparency regarding a significant institutional holder's stake, indicating a large financial institution's investment in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-07-29 | Previous Power of Attorney granted by The Goldman Sachs Group, Inc. was superseded. |
| 2024-10-01 | Previous Power of Attorney granted by Goldman Sachs & Co. LLC was superseded. |
| 2025-06-30 | Date of event which required the filing of this statement. |
| 2025-07-16 | Effective date of the new Power of Attorney for The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC. |
| 2025-08-01 | Date of filing of the Schedule 13G statement. |
| 2026-07-16 | Expiration date of the current Power of Attorney. |
Keywords
Goldman Sachs, Oaktree Acquisition Corp. III Life Sciences, Schedule 13G, Beneficial Ownership, Class A ordinary shares, Investment, Financial Services, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.